March 2026- Novartis announced that it has entered into an agreement to acquire Excellergy, Inc., a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases. The proposed acquisition adds Exl-111, a half-life extended, high-affinity anti-IgE antibody in Phase 1.

The acquisition builds on deep Novartis expertise in IgE biology and a long-standing presence in allergic disease. Exl-111 is designed as a next-generation extension of validated biology established by anti-IgE therapy, with the potential to complement the Novartis existing allergy portfolio across a range of allergic conditions and patient settings.

Click here to join our WhatsApp channel here

“Excellergy adds a differentiated next-generation anti-IgE program that builds on biology Novartis knows well, supported by preclinical evidence and early clinical pharmacokinetic data,” said Fiona Marshall, President of Biomedical Research at Novartis.

Also read: The GCC Menopause Hub Prepares to Host its First Summit in Abu Dhabi